p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F

Area of Science:

• Molecular Biology
• Cell Cycle Regulation
• Protein-Protein Interactions

Background:

• Cyclin-dependent kinase (CDK) activity is crucial for cell cycle progression.
• CDK inhibitors (CKIs) regulate CDK activity through complex formation.
• pRB-related proteins, like p107, are involved in cell cycle control.

Purpose of the Study:

• To investigate the inhibitory role of p107 on cyclin/CDK complexes.
• To compare the interaction mechanisms of p107 and p21 with cyclin/CDK2.
• To elucidate the functional consequences of p107-cyclin/CDK interactions.

Main Methods:

• Co-immunoprecipitation assays to study protein interactions.
• In vitro kinase assays to assess CDK activity.
• Analysis of protein complex dissociation in response to DNA damage.

Main Results:

• p107 inhibits cyclin A/CDK2 and cyclin E/CDK2, similar to p21.
• p107 and p21 bind to distinct, mutually exclusive sites on cyclin/CDK2 complexes.
• Elevated p21 levels disrupt p107/cyclin/CDK2 complexes, forming p21/cyclin/CDK2 complexes.
• Activation of p107-bound kinases causes p107 dissociation from E2F.

Conclusions:

• Cyclin/CDK complexes are regulated by different inhibitor families in a mutually exclusive manner.
• p107 and p21 act as distinct regulators of cyclin/CDK activity.
• These inhibitory interactions may play a role in regulating macromolecular assembly and cell cycle control.